ReviewFrontiers in endocrinology2023
Thyroid nodules: Global, economic, and personal burdens.
Review in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Ablative Technologies for Thyroid Nodules: A Health Technology Assessment.Ontario health technology assessment series · 2026Pooled it
- From economic burden to patient-centered solutions: the evolving landscape of financial toxicity in oncology.Frontiers in public health · 2026Pooled it
- Quality of life after endoscopic vs. conventional open thyroidectomy: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2025Pooled it
- Pooled it
- Application of Liquid-Based Cytology Using the ThinPrep System to Thyroid Fine-Needle Aspiration Samples.Current protocols · 2026Article
- Roles of External Factors and Polygenic Susceptibility in Thyroid Nodules and Goiter Among Children Aged 8-10 Years in Iodine-adequate Areas of Northern China.Biological trace element research · 2026Article
- Radiomics in thyroid nodule assessment.BMC medical imaging · 2026Review
- Precision medicine in thyroid nodules: current strategies, challenges, and future directions.Hormones (Athens, Greece) · 2026Review
- Assessing the accuracy of thyroid nodule risk-stratification tools in Hispanic and non-Hispanic patients.Journal of the Endocrine Society · 2026Article
- Conventional ultrasound combined with contrast-enhanced ultrasound for differentiating benign and malignant thyroid nodules.Quantitative imaging in medicine and surgery · 2026Article
- Comprehensive evaluation of TIR 3B thyroid nodules: Clinical, Ultrasonographical and Cytological features for prediction of malignancy.Endocrine · 2026Article
- LightGBM-guided discovery of mechanistic biomarkers in thyroid cancer: GALNT7 and SKP1P1 emerge as therapeutic targets.Discover oncology · 2026Article
- Causal Association of Dietary Habits With Thyroid Diseases: Univariate and Multivariate Mendelian Randomization Studies.Food science & nutrition · 2026Article
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma.Oncoscience · 2026Article
- Nomogram model for predicting papillary thyroid carcinoma based on clinical-ultrasound characteristics and inflammatory biomarkers: a multicenter study.Frontiers in oncology · 2026Article
- The association of neutrophils with the development of thyroid nodules: a cross-sectional study.Frontiers in oncology · 2026Article
- The Occurrence of Gene Fusions in Thyroid Lesions and the Relation With Chronic Lymphocytic Thyroiditis.Pathology international · 2026Article
- Spatial-Temporal Information Fusion for Thyroid Nodule Segmentation in Dynamic Contrast-Enhanced MRI: A Novel Approach.Journal of imaging informatics in medicine · 2025Article
- Prognostic role of the BRAF V600E variant in the preoperative biopsy in differentiated thyroid cancer.Journal of endocrinological investigation · 2025Article
- Conscientiousness personality is associated with increased thyroid nodule risk and sleep quality plays a masking role in this association.Scientific reports · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid nodules have garnered attention due to changes in population surveillance systems and rising concerns about the associated financial burden on healthcare systems, payers, and patients. In this review, we find that prevalence rates vary widely based on method of detection and may particularly pronounced in asymptomatic patients undergoing routine screening. Incidence rates may be particularly rising in lower-income and middle-income countries and may be declining in higher-income countries. Despite high incidence rates, survival rates continue to be as high as 97% for papillary thyroid cancer. Over the last few decades, thyroid nodule workup and management has grown more sophisticated with the advent of fine-needle aspiration biopsy, specialized biomarkers, and molecular testing. However, gaps remain in risk stratification that can lead to substantial costs of care. Certain molecular tests, such as the Afirma Gene Sequencing Classifier can lead to a cost per diagnosis of $17,873 while achieving only mild decreases in diagnostic lobectomies for patients (11.6% to 9.7% in one study). Out-of-pocket costs associated with thyroid nodule management continue to drive significant financial toxicity for patients, especially for individuals with thyroid cancer. Financial toxicity has been defined as a term that describes how direct and indirect medical costs of cancer care strain patients and households
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.